Amgen's Repatha Gets NHS Nod, But Sanofi's Praluent Misses Out
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE draft guidance lists Amgen's PCSK9 inhibitor as a therapeutic option for patients with primary hypercholesterolemia or mixed dyslipidemia, but not Sanofi/Regeneron's drug in the same class.